Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis

Future Journal of Pharmaceutical Sciences

Table 3 In vitro drug release kinetic study of the API from the various tenofovir and maraviroc bigel formulations

In vitro drug release kinetic study for maraviroc
	Zero order		First order		Higuchi		Korsmeyer-Peppas
Formulation	r²	k₀	r²	k₁	r²	k₂	r²	k₃
BG A	0.938	4.176	0.8323	0.0928	0.9702	28.22	0.9473	4.117
BG B	0.9355	3.8941	0.8529	0.0931	0.9662	26.30	0.9575	3.825
BG C	0.9179	4.309	0.8604	0.1166	0.9439	29.04	0.9502	1.834
BG D	0.776	3.833	0.7253	0.0912	0.8343	26.39	0.8538	4.077
In vitro drug release kinetic study for tenofovir
	Zero order		First order		Higuchi		Korsmeyer-Peppas
Formulation	r²	k₀	r²	k₁	Formulation	r²	k₀	r²
BG A	0.8412	4.0938	0.6362	0.0764	0.9000	28.14	0.8159	4.89
BG B	0.6979	2.7713	0.5532	0.0636	0.7781	19.45	0.7875	5.40
BG C	0.5171	2.1370	0.4575	0.056	0.6020	15.32	0.6882	5.84
BG D	0.6552	2.7074	0.5404	0.0653	0.7374	19.08	0.7859	4.74